Global Large Molecule Drug Substance CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Large Molecule Drug Substance CDMO Market is presumed to reach the market size of nearly USD 57.94 BN by 2030 from USD 22.71 BN in 2022 with a CAGR of 12.42% under the study period 2023 - 2030.

Large molecule drug substance CDMO refers to the contract development and manufacturing orGaNizations (CDMO) which provide services for processing large molecule drug substances. Large molecules are highly complex, have therapeutic effects and are prepared to resemble human proteins. It is one of the important steps for molecule production. It provides customers with services from drug development to manufacturing and, thus, assists the pharmaceutical industry. CDMO offers knowledge, development and manufacturing capabilities and provides crucial services by incorporating third-party projects.

Market Dynamics:

The key factor driving the demand for large molecule drug substance CDMO market is the rising cases of infectious diseases. Increasing large molecule drug approvals with FDA are contributing to the growth of this market. The growing pharmaceutical products demand due to the rising incidence of chronic diseases is surging the demand for this market. Continuous advancement in technology, increasing capital investment and establishment of partnerships by Pharma as well as biotech firms with CDMOs are expected to create several growth opportunities for this market over the forecast period. The rise in research and development activities associated with biologics and biosimilars is augmenting the demand for this market. Growth in cardiovascular diseases and CVD-induced deaths propel the demand for this market. However, stringent government regulations may obstruct the growth of this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of large molecule drug substance cdmo. The growth and trends of large molecule drug substance cdmo industry provide a holistic approach to this study.

Market Segmentation:

This section of the large molecule drug substance cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Service

Contract Manufacturing (Clinical, Commercial)
Contract Development (Cell Line Development, Process Development)

By Source

Mammalian
Microbial
Others

By End-User

Biotech Companies
CRO
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Large Molecule Drug Substance CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the large molecule drug substance cdmo market include Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112110346

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . LARGE MOLECULE DRUG SUBSTANCE CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Service
- 3.7.2 Market Attractiveness Analysis By Source
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SERVICE

6.1 Overview by Service
6.2 Historical and Forecast Data
6.3 Analysis by Service
6.4 Contract Manufacturing (Clinical, Commercial) Historic and Forecast Sales by Regions
6.5 Contract Development (Cell Line Development, Process Development) Historic and Forecast Sales by Regions

7 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET ANALYSIS BY SOURCE

7.1 Overview by Source
7.2 Historical and Forecast Data
7.3 Analysis by Source
7.4 Mammalian Historic and Forecast Sales by Regions
7.5 Microbial Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET SALES ANALYSIS BY END-USER

8.1 Overview by End-user
8.2 Historical and Forecast Data
8.3 Analysis by End-user
8.4 Biotech Companies Historic and Forecast Sales by Regions
8.5 CRO Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE LARGE MOLECULE DRUG SUBSTANCE CDMO COMPANIES

10.1. Large Molecule Drug Substance Cdmo Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Eurofins Scientific
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. WuXi Biologics
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Samsung Biologics
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Catalent Inc.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Rentschler Biopharma SE
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. AGC Biologics
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Recipharm AB
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Siegfried Holding AG
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Boehringer Ingelheim
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Fujifilm Diosynth Biotechnologies
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies